West Pharmaceutical Services to Present at Two Significant Investor Conferences This September

West Pharmaceutical Services' Upcoming Investor Conferences

West Pharmaceutical Services, Inc., a renowned leader in developing innovative solutions for injectable drug administration, has recently revealed its participation in two major investor conferences scheduled for September 2026. This announcement is set to enhance investor engagement and showcase the company's commitment to advancing healthcare solutions.

Conference Details

The first event is the Wells Fargo Annual Healthcare Conference, taking place on September 10, 2026, at 8:45 AM EDT, hosted in Everett, Massachusetts. The second is the Morgan Stanley Annual Global Healthcare Conference, happening on September 14, 2026, at 8:30 AM EDT, in New York City. These conferences are pivotal opportunities for West to connect with investors and present insights into its innovative approaches and market strategies.

West will be providing live webcasts for both conferences, which can be accessed through the Investor Relations section of their official website. For those unable to attend live, replays of the webcasts will be available for approximately 90 days following each event, ensuring all interested parties can stay informed about the company's progress and strategies.

About West Pharmaceutical Services

Founded in 1923 and headquartered in Exton, Pennsylvania, West Pharmaceutical Services, Inc. is focused on producing high-quality injectable solutions and services. As a trusted partner for both established and emerging pharmaceutical developers, West plays a critical role in ensuring the safe and effective containment and delivery of essential medicines designed to enhance and save lives.

The company operates more than 50 sites globally, including 26 manufacturing facilities, and employs over 10,000 professionals dedicated to delivering more than 41 billion components and devices each year. This extensive reach underscores West's pivotal role in the healthcare supply chain and its commitment to quality and innovation.

In the fiscal year 2025, West generated impressive net sales of $3.07 billion, a testament to its significant market presence and strong operational performance. West Pharmaceutics is publicly traded on the New York Stock Exchange under the ticker symbol NYSE: WST and is part of the prestigious Standard & Poor's 500 index.

The participation of West Pharmaceutical Services at these forthcoming conferences not only highlights its strategic priorities but also reinforces its commitment to transparency and investor communication within the pharmaceutical industry. We look forward to seeing how these discussions will unfold and what initiatives will emerge from these engagements, further contributing to West’s trajectory in the healthcare landscape.

For more information about West and its innovative products and services, visit www.westpharma.com.

Conclusion

As West Pharmaceutical Services engages with investors at these critical events, they reaffirm their position at the forefront of pharmaceutical innovation, dedicated to improving the delivery of healthcare solutions across the globe. Keep an eye on their updates following the conferences for the latest developments from this key player in the industry.